1
|
Ercanbrack CW, Azhari JO, Warner DB, Abulfaraj M, Elhusseiny AM. Unusual Pediatric Red Eye. J Pediatr 2024; 267:113924. [PMID: 38272109 DOI: 10.1016/j.jpeds.2024.113924] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/08/2024] [Revised: 01/17/2024] [Accepted: 01/18/2024] [Indexed: 01/27/2024]
Affiliation(s)
- Carson W Ercanbrack
- College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR
| | - Jamal O Azhari
- Department of Ophthalmology, Harvey and Bernice Jones Eye Institute, University of Arkansas for Medical Sciences, Little Rock, AR
| | - David B Warner
- Department of Ophthalmology, Harvey and Bernice Jones Eye Institute, University of Arkansas for Medical Sciences, Little Rock, AR
| | - Maher Abulfaraj
- Department of Emergency Medicine, Arkansas Children's Hospital, Little Rock, AR
| | - Abdelrahman M Elhusseiny
- Harvey and Bernice Jones Eye Institute, University of Arkansas for Medical Sciences, Little Rock, AR; Department of Ophthalmology, Boston Children's Hospital, Boston, MA
| |
Collapse
|
2
|
Sen M, Demirci H, Honavar SG. Targeted therapy in ophthalmic oncology: The current status. Asia Pac J Ophthalmol (Phila) 2024; 13:100062. [PMID: 38642707 DOI: 10.1016/j.apjo.2024.100062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2024] [Revised: 04/08/2024] [Accepted: 04/08/2024] [Indexed: 04/22/2024] Open
Abstract
There have been rapid advancements in the field of ocular oncology for the diagnosis and management of intraocular, adnexal, and orbital tumors. Targeted therapy is in the forefront of medical research in all fields including ocular oncology. Targeted therapy include drugs that target specific genetic mutations, pathways or proteins involved in the development of cancer. In contrast to traditionally used chemotherapy, drugs used in targeted therapy are highly specific for tumor cells and preserve the function of normal cells. This review aims to familiarize ophthalmologists with the drugs that are currently approved or undergoing clinical trials for use in ocular oncology. Targeted therapy is particularly useful for locally advanced or metastatic tumors, including but not limited to eyelid and periocular basal cell carcinoma, periocular cutaneous and conjunctival squamous cell carcinoma, ocular adnexal lymphoma, conjunctival melanoma, and uveal melanoma. The results are promising with improved survival outcomes and better tolerability than chemotherapeutic drugs.
Collapse
Affiliation(s)
- Mrittika Sen
- Ocular Oncology Service, Raghunath Netralaya, Mumbai, India
| | - Hakan Demirci
- Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, MI, USA
| | - Santosh G Honavar
- Ocular Oncology Service, Centre for Sight Eye Hospital, Hyderabad, India.
| |
Collapse
|
3
|
Luo Y, Huang Z, Gao Z, Wang B, Zhang Y, Bai Y, Wu Q, Wang M. Prognostic Value of 18F-FDG PET/CT Radiomics in Extranodal Nasal-Type NK/T Cell Lymphoma. Korean J Radiol 2024; 25:189-198. [PMID: 38288898 PMCID: PMC10831304 DOI: 10.3348/kjr.2023.0618] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2023] [Revised: 11/08/2023] [Accepted: 11/16/2023] [Indexed: 02/01/2024] Open
Abstract
OBJECTIVE To investigate the prognostic utility of radiomics features extracted from 18F-fluorodeoxyglucose (FDG) PET/CT combined with clinical factors and metabolic parameters in predicting progression-free survival (PFS) and overall survival (OS) in individuals diagnosed with extranodal nasal-type NK/T cell lymphoma (ENKTCL). MATERIALS AND METHODS A total of 126 adults with ENKTCL who underwent 18F-FDG PET/CT examination before treatment were retrospectively included and randomly divided into training (n = 88) and validation cohorts (n = 38) at a ratio of 7:3. Least absolute shrinkage and selection operation Cox regression analysis was used to select the best radiomics features and calculate each patient's radiomics scores (RadPFS and RadOS). Kaplan-Meier curve and Log-rank test were used to compare survival between patient groups risk-stratified by the radiomics scores. Various models to predict PFS and OS were constructed, including clinical, metabolic, clinical + metabolic, and clinical + metabolic + radiomics models. The discriminative ability of each model was evaluated using Harrell's C index. The performance of each model in predicting PFS and OS for 1-, 3-, and 5-years was evaluated using the time-dependent receiver operating characteristic (ROC) curve. RESULTS Kaplan-Meier curve analysis demonstrated that the radiomics scores effectively identified high- and low-risk patients (all P < 0.05). Multivariable Cox analysis showed that the Ann Arbor stage, maximum standardized uptake value (SUVmax), and RadPFS were independent risk factors associated with PFS. Further, β2-microglobulin, Eastern Cooperative Oncology Group performance status score, SUVmax, and RadOS were independent risk factors for OS. The clinical + metabolic + radiomics model exhibited the greatest discriminative ability for both PFS (Harrell's C-index: 0.805 in the validation cohort) and OS (Harrell's C-index: 0.833 in the validation cohort). The time-dependent ROC analysis indicated that the clinical + metabolic + radiomics model had the best predictive performance. CONCLUSION The PET/CT-based clinical + metabolic + radiomics model can enhance prognostication among patients with ENKTCL and may be a non-invasive and efficient risk stratification tool for clinical practice.
Collapse
Affiliation(s)
- Yu Luo
- Department of Medical Imaging, Henan Provincial People's Hospital, The People's Hospital of Zhengzhou University, Zhengzhou, China
- Academy of Medical Sciences, Zhengzhou University, Zhengzhou, China
| | - Zhun Huang
- Department of Medical Imaging, Henan Provincial People's Hospital, The People's Hospital of Zhengzhou University, Zhengzhou, China
| | - Zihan Gao
- Department of Medical Imaging, Henan Provincial People's Hospital, The People's Hospital of Zhengzhou University, Zhengzhou, China
| | - Bingbing Wang
- Department of Medical Imaging, Henan Provincial People's Hospital, The People's Hospital of Zhengzhou University, Zhengzhou, China
| | - Yanwei Zhang
- Department of Bethune International Peace Hospital, Department of Radiology, Shijiazhuang, China
| | - Yan Bai
- Department of Medical Imaging, Henan Provincial People's Hospital, The People's Hospital of Zhengzhou University, Zhengzhou, China
| | - Qingxia Wu
- Beijing United Imaging Research Institute of Intelligent Imaging, Beijing, China
| | - Meiyun Wang
- Department of Medical Imaging, Henan Provincial People's Hospital, The People's Hospital of Zhengzhou University, Zhengzhou, China
- Henan Key Laboratory for Medical Imaging of Neurological Diseases, Zhengzhou, China
- Laboratory of Brain Science and Brain-Like Intelligence Technology, Institute for Integrated Medical Science and Engineering, Henan Academy of Sciences, Zhengzhou, China.
| |
Collapse
|
4
|
Serbest Ceylanoglu K, Guneri Beser B, Singalavanija T, Juntipwong S, Worden FP, Demirci H. Targeted Therapy and Immunotherapy for Advanced Malignant Conjunctival Tumors: Systematic Review. Ophthalmic Plast Reconstr Surg 2024; 40:18-29. [PMID: 38241616 DOI: 10.1097/iop.0000000000002488] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2024]
Abstract
PURPOSE To review the outcomes of targeted therapy and immunotherapy in advanced conjunctival tumors, including conjunctival squamous cell carcinoma, conjunctival melanoma, and conjunctival lymphoma. METHODS A Pubmed database systematic search was performed between January 1999 and December 2022. The literature search was limited to studies published in English. RESULTS This review included 142 patients with advanced malignant conjunctival tumors from 42 articles. In the conjunctival squamous cell carcinoma group, 2 cases of advanced conjunctival squamous cell carcinoma treated with epidermal growth factor receptor inhibitors showed significant tumor size improvement after 7.5 months of follow-up. Among 7 cases treated with systemic immunotherapy, 5 cases (72%) had complete response (CR), 1 case (14%) showed partial response (PR), and 1 case (14%) had stable disease (SD) after 16 months. In the conjunctival melanoma group, among 18 cases treated with combined v-raf murine sarcoma viral oncogene homolog B1/mitogen-activated extracellular signal-regulated kinase inhibitors, 6 (33%) had CR, 5 (28%) had PR, 2 (11%) had SD, and 5 (28%) had progressive disease after 24.8 months of follow-up. Of 44 conjunctival melanoma cases treated with immunotherapy, 12 (28%) had CR, 9 (20%) had PR, 7(16%) had SD, and 16 (36%) had progressive disease after 14.2 months. Systemic Rituximab treatment for conjunctival lymphoma cases resulted in CR in 21 patients (63%), PR in 11 patients (33%), and SD in 1 patient (3%) after 20.5 months of follow-up. Intralesional Rituximab injections in 38 conjunctival lymphoma cases showed CR in 28 patients (75%), PR in 7 patients (19%), SD in 1 patient (2%), and progressive disease in 2 patients (4%) after 20.4 months of follow-up. CONCLUSIONS Despite limited clinical case reports and short-term follow-ups, targeted therapy and immunotherapy have shown promising results for advanced malignant conjunctival tumors.
Collapse
Affiliation(s)
- Kubra Serbest Ceylanoglu
- Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, MI, U.S.A
- Department of Ophthalmology, University of Health Sciences, Ulucanlar Eye Training and Research Hospital, Ankara, Turkiye
| | - Buse Guneri Beser
- Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, MI, U.S.A
| | - Tassapol Singalavanija
- Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, MI, U.S.A
- Department of Ophthalmology, Chulabhorn Hospital, HRH Princess Chulabhorn College of Medical Science, Chulabhorn Royal Academy, Bangkok, Thailand
| | - Sarinee Juntipwong
- Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, MI, U.S.A
| | - Francis Paul Worden
- Division of Hematology-Oncology, Department of Internal Medicine, Roger Cancer Center, University of Michigan, Ann Arbor, Michigan, U.S.A
| | - Hakan Demirci
- Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, MI, U.S.A
| |
Collapse
|
5
|
Hoffmann C, Ringbaek T, Eckstein A, Deya W, Santiago A, Heintz M, Lübcke W, Indenkämpen F, Sauerwein W, Flühs A, Le Guin C, Huettmann A, von Tresckow J, Göricke S, Deuschl C, Moliavi S, Poettgen C, Gauler T, Guberina N, Johansson P, Bechrakis N, Stuschke M, Guberina M. Long-Term Follow-Up of Patients with Conjunctival Lymphoma after Individualized Lens-Sparing Electron Radiotherapy: Results from a Longitudinal Study. Cancers (Basel) 2023; 15:5433. [PMID: 38001692 PMCID: PMC10670077 DOI: 10.3390/cancers15225433] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2023] [Revised: 11/02/2023] [Accepted: 11/11/2023] [Indexed: 11/26/2023] Open
Abstract
Irradiation with electrons is the primary treatment regime for localized conjunctival low-grade lymphomas. However, radiation-induced cataracts are a major cause of treatment-related morbidity. This study investigates whether lens-sparing electron irradiation produces sufficient disease control rates while preventing cataract formation. All consecutive patients with strictly conjunctival, low-grade Ann Arbor stage IE lymphoma treated with superficial electron irradiation between 1999 and 2021 at our department were reviewed. A total of 56 patients with 65 treated eyes were enrolled with a median follow-up of 65 months. The median dose was 30.96 Gy. A lens-spearing technique featuring a hanging rod blocking the central beam axis was used in 89.2% of all cases. Cumulative incidences of 5- and 10-year infield recurrences were 4.3% and 14.6%, incidences of 5- and 10-year outfield progression were 10.4% and 13.4%. We used patients with involvement of retroorbital structures treated with whole-orbit photon irradiation without lens protection-of which we reported in a previous study-as a control group. The cumulative cataract incidence for patients treated with electrons and lens protection was significantly lower (p = 0.005) when compared to patients irradiated without lens protection. Thus, electrons are an effective treatment option for conjunctival low-grade lymphomas. The presented lens-sparing technique effectively prevents cataract formation.
Collapse
Affiliation(s)
- Christian Hoffmann
- Department of Radiotherapy, West German Cancer Centre, University Hospital Essen, 45147 Essen, Germany (M.G.)
- National Center for Tumor Diseases (NCT) West, Campus Essen, 45147 Essen, Germany
| | - Toke Ringbaek
- Department of Radiotherapy, West German Cancer Centre, University Hospital Essen, 45147 Essen, Germany (M.G.)
- National Center for Tumor Diseases (NCT) West, Campus Essen, 45147 Essen, Germany
- Department of Radiotherapy, Medical Physics Section, University Hospital Essen, 45147 Essen, Germany
| | - Anja Eckstein
- National Center for Tumor Diseases (NCT) West, Campus Essen, 45147 Essen, Germany
- Department of Ophthalmology, West German Cancer Centre, University Hospital Essen, 45147 Essen, Germany
| | - Wolfgang Deya
- Department of Radiotherapy, West German Cancer Centre, University Hospital Essen, 45147 Essen, Germany (M.G.)
- National Center for Tumor Diseases (NCT) West, Campus Essen, 45147 Essen, Germany
- Department of Radiotherapy, Medical Physics Section, University Hospital Essen, 45147 Essen, Germany
| | - Alina Santiago
- Department of Radiotherapy, West German Cancer Centre, University Hospital Essen, 45147 Essen, Germany (M.G.)
- National Center for Tumor Diseases (NCT) West, Campus Essen, 45147 Essen, Germany
- Department of Radiotherapy, Medical Physics Section, University Hospital Essen, 45147 Essen, Germany
| | - Martin Heintz
- Department of Radiotherapy, West German Cancer Centre, University Hospital Essen, 45147 Essen, Germany (M.G.)
- National Center for Tumor Diseases (NCT) West, Campus Essen, 45147 Essen, Germany
- Department of Radiotherapy, Medical Physics Section, University Hospital Essen, 45147 Essen, Germany
| | - Wolfgang Lübcke
- Department of Radiotherapy, West German Cancer Centre, University Hospital Essen, 45147 Essen, Germany (M.G.)
- National Center for Tumor Diseases (NCT) West, Campus Essen, 45147 Essen, Germany
- Department of Radiotherapy, Medical Physics Section, University Hospital Essen, 45147 Essen, Germany
| | - Frank Indenkämpen
- Department of Radiotherapy, West German Cancer Centre, University Hospital Essen, 45147 Essen, Germany (M.G.)
- Department of Radiotherapy, Medical Physics Section, University Hospital Essen, 45147 Essen, Germany
| | - Wolfgang Sauerwein
- Department of Radiotherapy, West German Cancer Centre, University Hospital Essen, 45147 Essen, Germany (M.G.)
| | - Andrea Flühs
- Department of Radiotherapy, West German Cancer Centre, University Hospital Essen, 45147 Essen, Germany (M.G.)
- Department of Radiotherapy, Medical Physics Section, University Hospital Essen, 45147 Essen, Germany
| | - Claudia Le Guin
- National Center for Tumor Diseases (NCT) West, Campus Essen, 45147 Essen, Germany
- Department of Ophthalmology, West German Cancer Centre, University Hospital Essen, 45147 Essen, Germany
| | - Andreas Huettmann
- National Center for Tumor Diseases (NCT) West, Campus Essen, 45147 Essen, Germany
- Department of Hematology, West German Cancer Centre, University Hospital Essen, 45147 Essen, Germany
| | - Julia von Tresckow
- National Center for Tumor Diseases (NCT) West, Campus Essen, 45147 Essen, Germany
- Department of Hematology, West German Cancer Centre, University Hospital Essen, 45147 Essen, Germany
| | - Sophia Göricke
- National Center for Tumor Diseases (NCT) West, Campus Essen, 45147 Essen, Germany
- Institute for Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, 45147 Essen, Germany
| | - Cornelius Deuschl
- National Center for Tumor Diseases (NCT) West, Campus Essen, 45147 Essen, Germany
- Institute for Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, 45147 Essen, Germany
| | - Sourour Moliavi
- Department of Radiotherapy, West German Cancer Centre, University Hospital Essen, 45147 Essen, Germany (M.G.)
- National Center for Tumor Diseases (NCT) West, Campus Essen, 45147 Essen, Germany
| | - Christoph Poettgen
- Department of Radiotherapy, West German Cancer Centre, University Hospital Essen, 45147 Essen, Germany (M.G.)
- National Center for Tumor Diseases (NCT) West, Campus Essen, 45147 Essen, Germany
| | - Thomas Gauler
- Department of Radiotherapy, West German Cancer Centre, University Hospital Essen, 45147 Essen, Germany (M.G.)
- National Center for Tumor Diseases (NCT) West, Campus Essen, 45147 Essen, Germany
| | - Nika Guberina
- Department of Radiotherapy, West German Cancer Centre, University Hospital Essen, 45147 Essen, Germany (M.G.)
- National Center for Tumor Diseases (NCT) West, Campus Essen, 45147 Essen, Germany
| | - Patricia Johansson
- National Center for Tumor Diseases (NCT) West, Campus Essen, 45147 Essen, Germany
- Institute of Cell Biology (Cancer Research), Faculty of Medicine, University of Duisburg-Essen, 45147 Essen, Germany
| | - Nikolaos Bechrakis
- National Center for Tumor Diseases (NCT) West, Campus Essen, 45147 Essen, Germany
- Department of Ophthalmology, West German Cancer Centre, University Hospital Essen, 45147 Essen, Germany
| | - Martin Stuschke
- Department of Radiotherapy, West German Cancer Centre, University Hospital Essen, 45147 Essen, Germany (M.G.)
- National Center for Tumor Diseases (NCT) West, Campus Essen, 45147 Essen, Germany
- German Cancer Consortium (DKTK), Partner Site University Hospital Essen, 45147 Essen, Germany
| | - Maja Guberina
- Department of Radiotherapy, West German Cancer Centre, University Hospital Essen, 45147 Essen, Germany (M.G.)
- National Center for Tumor Diseases (NCT) West, Campus Essen, 45147 Essen, Germany
- German Cancer Consortium (DKTK), Partner Site University Hospital Essen, 45147 Essen, Germany
| |
Collapse
|
6
|
Florou C, Aissopou E, Papakonstantinou E, Georgalas I, Droutsas K. Conjunctival Marginal Zone Lymphoma in a Patient With Neurofibromatosis Type 1: A Case Report. Cureus 2023; 15:e49491. [PMID: 38152792 PMCID: PMC10752339 DOI: 10.7759/cureus.49491] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/27/2023] [Indexed: 12/29/2023] Open
Abstract
We present a case of painless bulbar conjunctival mass due to B-cell non-Hodgkin lymphoma (NHL), without systemic involvement, in a 76-year-old man. Following an excision biopsy, histopathologic examination and immunohistochemistry confirmed the diagnosis, prompting a referral for hemato-oncological assessment. The patient underwent comprehensive laboratory and imaging scans, subsequently receiving combined chemo-immunotherapy that resulted in complete remission to date. This case is reported as it is crucial to recognize that a conjunctival insult might emerge in neurofibromatosis type 1 (NF1) patients.
Collapse
Affiliation(s)
- Chrysoula Florou
- Department of Ophthalmology, National and Kapodistrian University of Athens, General Hospital "G. Gennimatas", Athens, GRC
| | | | - Evangelia Papakonstantinou
- Department of Ophthalmology, National and Kapodistrian University of Athens, General Hospital "G. Gennimatas", Athens, GRC
| | - Ilias Georgalas
- Department of Ophthalmology, National and Kapodistrian University of Athens, General Hospital "G. Gennimatas", Athens, GRC
| | - Konstantinos Droutsas
- Department of Ophthalmology, National and Kapodistrian University of Athens, General Hospital "G. Gennimatas", Athens, GRC
| |
Collapse
|
7
|
Lin Y, Liu X, Zhang Y, Xie Z, Fang X, Shi K, Zhong Y, Su S, Cai M, Wu H, Ou S. The clinicopathological analysis of ocular and orbit tumors in southeast of China. Front Oncol 2023; 13:1118862. [PMID: 37404770 PMCID: PMC10316389 DOI: 10.3389/fonc.2023.1118862] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2022] [Accepted: 04/21/2023] [Indexed: 07/06/2023] Open
Abstract
Purpose The purpose of this study is to describe the clinicopathologic characteristics of ocular surface and orbit tumors in the Southeast of China and explore the method to differentiate the benign and malignant masses. Materials and methods 3468 patients undergoing mass resection from January 2015 to December 2020 were selected as observation subjects and were classified into benign and malignant masses according to postoperative pathology. The clinicopathologic characteristics were collected, including gender, age, pathological tissue signs, and pathological signs. Multivariate Logistic regression analysis of independent risk factors of malignant mass was applied to establish a diagnostic model and the efficacy was evaluated by the subject working characteristics (ROC) curve. Results Benign tumors accounted for 91.5% of all cases, and malignant tumors accounted for 8.5%. The most common ocular benign tumors were nevi (24.2%), granuloma (17.1%), and cysts (16.4%). The most common ocular malignant tumors were malignant lymphoma (32.1%) and Basal cell carcinoma (20.2%). As for the histologic origin, melanocytic origin was on the list with 819 (23.6%), mesenchymal 661 (19.1%), epithelial 568 (16.3%), cystic 521 (15.0%), skin adnexal 110 (3.1%), lymphoid 94 (2.8%), and Neural 25(0.8%). Based on the gender, age, tumor location, and the pathological tissue image feature (including differentiation, structural atypia, covering epithelial, keratosis, nest structure/distribution, nuclear atypia, cytoplasmic change and nuclear division), the diagnostic model had predictive value to differentiate the benign and malignant masses. Conclusion Most ocular surface and orbit tumors are benign. Tumor diagnosis is relative to the patient's age, gender, tumor location, and pathologic characteristics. We generated a satisfactory diagnostic model to differential diagnosis of benign and malignant masses.
Collapse
Affiliation(s)
- Yuan Lin
- Eye Institute of Xiamen University and affiliated Xiamen Eye Center, School of Medicine, Xiamen University, Xiamen, Fujian, China
- Fujian Provincial Key Laboratory of Corneal & Ocular Surface Diseases, Xiamen, Fujian, China
| | - Xiaodong Liu
- Eye Institute of Xiamen University and affiliated Xiamen Eye Center, School of Medicine, Xiamen University, Xiamen, Fujian, China
- Fujian Provincial Key Laboratory of Corneal & Ocular Surface Diseases, Xiamen, Fujian, China
| | - Yujie Zhang
- Eye Institute of Xiamen University and affiliated Xiamen Eye Center, School of Medicine, Xiamen University, Xiamen, Fujian, China
- Fujian Provincial Key Laboratory of Corneal & Ocular Surface Diseases, Xiamen, Fujian, China
| | - Zhiwen Xie
- Eye Institute of Xiamen University and affiliated Xiamen Eye Center, School of Medicine, Xiamen University, Xiamen, Fujian, China
- Fujian Provincial Key Laboratory of Corneal & Ocular Surface Diseases, Xiamen, Fujian, China
| | - Xie Fang
- Eye Institute of Xiamen University and affiliated Xiamen Eye Center, School of Medicine, Xiamen University, Xiamen, Fujian, China
- Fujian Provincial Key Laboratory of Corneal & Ocular Surface Diseases, Xiamen, Fujian, China
| | - Ke Shi
- Eye Institute of Xiamen University and affiliated Xiamen Eye Center, School of Medicine, Xiamen University, Xiamen, Fujian, China
- Fujian Provincial Key Laboratory of Corneal & Ocular Surface Diseases, Xiamen, Fujian, China
| | - Yanlin Zhong
- Eye Institute of Xiamen University and affiliated Xiamen Eye Center, School of Medicine, Xiamen University, Xiamen, Fujian, China
- Fujian Provincial Key Laboratory of Corneal & Ocular Surface Diseases, Xiamen, Fujian, China
| | - Shengqi Su
- Eye Institute of Xiamen University and affiliated Xiamen Eye Center, School of Medicine, Xiamen University, Xiamen, Fujian, China
- Fujian Provincial Key Laboratory of Corneal & Ocular Surface Diseases, Xiamen, Fujian, China
- Xiamen Science and Technology Middle School, Xiamen, Fujian, China
| | - Minqing Cai
- Eye Institute of Xiamen University and affiliated Xiamen Eye Center, School of Medicine, Xiamen University, Xiamen, Fujian, China
- Fujian Provincial Key Laboratory of Corneal & Ocular Surface Diseases, Xiamen, Fujian, China
| | - Huping Wu
- Eye Institute of Xiamen University and affiliated Xiamen Eye Center, School of Medicine, Xiamen University, Xiamen, Fujian, China
- Fujian Provincial Key Laboratory of Corneal & Ocular Surface Diseases, Xiamen, Fujian, China
| | - Shangkun Ou
- Eye Institute of Xiamen University and affiliated Xiamen Eye Center, School of Medicine, Xiamen University, Xiamen, Fujian, China
- Fujian Provincial Key Laboratory of Corneal & Ocular Surface Diseases, Xiamen, Fujian, China
| |
Collapse
|
8
|
Chadha V, Sagoo MS. Ocular oncology demystified. Eye (Lond) 2023; 37:795-796. [PMID: 36513857 PMCID: PMC10049976 DOI: 10.1038/s41433-022-02343-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2022] [Revised: 11/30/2022] [Accepted: 11/30/2022] [Indexed: 12/15/2022] Open
Affiliation(s)
- Vikas Chadha
- Scottish Ocular Oncology Service, Tennent Institute of Ophthalmology, Gartnavel General Hospital, Glasgow, UK.
| | - Mandeep S Sagoo
- Ocular Oncology Service, Moorfields Eye Hospital; Retinoblastoma Service, The Royal London Hospital; and NIHR Biomedical Research Centre for Ophthalmology, Moorfields Eye Hospital and UCL Institute of Ophthalmology, London, UK.
| |
Collapse
|
9
|
Transcriptional Profiling Identifies Prognostic Gene Signatures for Conjunctival Extranodal Marginal Zone Lymphoma. Biomolecules 2023; 13:biom13010115. [PMID: 36671500 PMCID: PMC9855408 DOI: 10.3390/biom13010115] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2022] [Revised: 12/30/2022] [Accepted: 01/02/2023] [Indexed: 01/11/2023] Open
Abstract
This study characterizes the transcriptional profile and the cellular tumor microenvironment of conjunctival extranodal marginal zone lymphoma (EMZL) and identifies prognostically relevant biomarkers. Ten formalin-fixed and paraffin-embedded conjunctival EMZL and eight healthy conjunctival specimens were analyzed by Massive Analysis of cDNA Ends (MACE) RNA sequencing. The 3417 upregulated genes in conjunctival EMZL were involved in processes such as B cell proliferation and Rac protein signaling, whereas the 1188 downregulated genes contributed most significantly to oxidative phosphorylation and UV protection. The tumor microenvironment, as determined by deconvolution analysis, was mainly composed of multiple B cell subtypes which reflects the tumor's B cell lineage. However, several T cell types, including T helper 2 cells and regulatory T cells, as well as innate immune cell types, such as anti-inflammatory macrophages and plasmacytoid dendritic cells, were also strongly enriched in conjunctival EMZL. A 13-biomarker prognostic panel, including S100A8 and S100A9, classified ocular and extraocular tumor recurrence, exceeded prognostic accuracy of Ann Arbor and American Joint Committee on Cancer (AJCC) staging, and demonstrated prognostic value for patient survival in 21 different cancer types in a database of 12,332 tumor patients. These findings may lead to new options of targeted therapy and may improve prognostic prediction for conjunctival EMZL.
Collapse
|
10
|
Cunningham ET, Ng C, Suhler EB, Smit DP. Rituximab for Ocular Inflammatory Disease. Ocul Immunol Inflamm 2022; 30:1300-1302. [PMID: 36379016 DOI: 10.1080/09273948.2022.2141034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Emmett T Cunningham
- The Department of Ophthalmology, California Pacific Medical Center, San Francisco, CA, USA
- The Department of Ophthalmology, Stanford University School of Medicine, Stanford, CA, USA
- The Francis I. Proctor Foundation, UCSF School of Medicine, San Francisco, CA, USA
| | - Caleb Ng
- Retina Consultants of Orange County, Fullerton, CA, USA
| | - Eric B Suhler
- OHSU-PSU School of Public Health, and VA Portland Health Care System, Casey Eye Institute, Oregon Health & Science University, Portland, Oregon, USA
| | - Derrick P Smit
- Division of Ophthalmology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
| |
Collapse
|